Detail akcie GlucoTrack Rg online

Business Summary: Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, GlucoTrack Inc revenues was not reported. Net loss increased 26% to $15.8M. Higher net loss reflects Other Net Financial Income/Expenses increase from $2K to $3.3M (expense), General and administrative expenses increase of 53% to $4M (expense), Research and development expenses increase of 5% to $8.2M (expense).